Search

Search Constraints

You searched for: Author/Creator Cho, Jang Ho

Search Results

3. Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. (October 2018)

4. Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real‐world data (KCSG LU20‐11). Issue 4 (27th October 2021)